Results 1 to 10 of about 14,123 (118)
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2021 We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n ...
Soon-Jib Yoo +8 more
doaj +1 more source
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
Frontiers in Pharmacology, 2021 Mycobacterium abscessus is a difficult respiratory pathogen to treat, when compared to other nontuberculus mycobacteria (NTM), due to its drug resistance.
Bui Thi Bich Hanh +7 more
doaj +1 more source
Basic principles of combination therapy: focus on drug-drug interaction
Кардиоваскулярная терапия и профилактика, 2021 The article is devoted to the issue of drug interactions in the combination regimens. Today, when drug therapy is the first-line approach for patients with noncommunicable diseases, and the world population ageing leads to an increase in the number of ...
S. Yu. Martsevich +2 more
doaj +1 more source
Exploratory Research in Clinical and Social Pharmacy, 2021 Background: Drug interactions are important causes of adverse events. Assessments of pharmacological interactions outside healthcare services settings are scarce. Objective: To assess the frequency and factors associated with these potential interactions
Tayanny Margarida Menezes Almeida Biase +2 more
doaj +1 more source
MedComm – Biomaterials and Applications, 2023 Various nanocarriers have been explored to deliver drugs for combination therapy. However, most nanocarriers are composed of inert materials without contribution for improving the cancer therapeutic effect.
Jingqi Xin +3 more
doaj +1 more source
Nanoparticles for Combination Drug Therapy [PDF]
ACS Nano, 2013 Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted ...
Liang, Ma, Manish, Kohli, Andrew, Smith
openaire +2 more sources
High Drug-Loading Nanomedicines for Tumor Chemo–Photo Combination Therapy: Advances and Perspectives
Pharmaceutics, 2022 The combination of phototherapy and chemotherapy (chemo–photo combination therapy) is an excellent attempt for tumor treatment. The key requirement of this technology is the high drug-loading nanomedicines, which can load either chemotherapy drugs or ...
Ya Wang +6 more
doaj +1 more source
Understanding and targeting resistance mechanisms in cancer
MedComm, 2023 Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes of treatment failure and poor patient survival. The reduced responsiveness of cancer cells is a multifaceted phenomenon that can
Zi‐Ning Lei +6 more
doaj +1 more source
Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study [PDF]
Diabetes & Metabolism Journal, 2020 BackgroundThere is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy.
Jeong Mi Kim +12 more
doaj +1 more source
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming [PDF]
Diabetes & Metabolism Journal, 2020 The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%.
Soung Won Jeong
doaj +1 more source